FDA approves Novo nordisk Fiasp (Mendon Insulin Injection) 100u/mL label extension

recently announced that the U.SFood andDrug(http://Administration http://
(http:// has approved the Fiasp (Mendin insulin injection) 100u/mL label extensionFiasp is a quick-acting insulin that was approved by the FDA in 2017 to treat adult patients with diabetes with intravenous infusions or subcutaneous multiple injections (MDI) under the supervision ofMedical(http://professionalsFiasp is the first and only quick-acting insulin injection that does not have a pre-meal prescription, which is given before meals or within 20 minutes of starting the mealFiasp has a variety of dose options for multiple daily injections (MDI) and continuous subcutaneous insulin infusions:(1) 10mL small bottles for insulin pump or MDI;Fiasp is closer to the natural physiological insulin response after a meal without diabetics than conventional winter insulinTo date, Fiasp has been approved by the United States, the European Union, Canada, Australia, Switzerland and other markets for adult sesame and improved blood sugar control in adult patients with type 1 and type 2 diabetes